Results 141 to 150 of about 46,900 (298)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek +5 more
wiley +1 more source
Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber +10 more
wiley +1 more source
Understanding how enzymes work: the journey to ensemble–function studies
The FEBS Journal, EarlyView.For decades, structure–function has dominated biochemistry. Structures are highly valuable, yet more is needed to achieve a quantitative understanding of biomolecular function, because function emerges from an ensemble of states, rather than a static structure. We describe an ensemble–function framework applied to quantitatively dissect serine protease
Daniel Herschlag, Siyuan Du
wiley +1 more source
Heart Failure and Dipeptidyl Peptidase-4 Inhibitors [PDF]
European Journal of Heart Failure, 2014 Henry, Krum +3 more
openaire +2 more sources
Hepatology Research, EarlyView.Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
The Role of Neuropeptide Y in Dental Pulp: Balancing Neurogenic Inflammation and Pain Modulation
International Endodontic Journal, EarlyView.ABSTRACT Background Dental pulp is a densely innervated, low‐compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene‐related peptide (CGRP) are well‐established drivers of pulp vasodilation, the Neuroopeptide Y (NPY ...
Javier Caviedes‐Bucheli +3 more
wiley +1 more source